Companies / BSX vs DXCM
BSX vs DXCM: Boston Scientific and Dexcom
Boston Scientific (BSX) reported $20.1B in revenue against a 14.4% net margin, while Dexcom (DXCM) reported $4.7B at a 17.9% net margin, most recently.
| Metric | BSX | DXCM |
|---|---|---|
| Revenue | $20.1B | $4.7B |
| Net Income | $2.9B | $0.8B |
| Gross Margin | 69.0% | 60.1% |
| Operating Margin | 18.0% | 19.6% |
| EPS (Diluted) | $1.94 | $2.09 |
| Free Cash Flow | $3.7B | $1.1B |
| Total Debt | $11.4B | $1.3B |
| P/E Ratio | 49.2× | 31.8× |
| P/B Ratio | n/m | 9.3× |
| Stock Price | $44.62 | $84.45 |
Free: last 5 years
| Fiscal year | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| DXCM Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |